Podcast: Play in new window | Download

Subscribe: Android | RSS

This week on The Green Rush, Anne and Nick are back with a new episode with guest Bob Dagher, Chief Medical Officer at Enveric Biosciences (NASDAQ: ENVB), a cutting-edge neuroscience company developing next-generation, psychedelic-inspired mental health medicines.

Leading the company’s drug development and commercialization efforts, Bob has a long history helping life sciences companies to create innovative solutions that meet the needs of millions of patients around the world. At Enveric, he is currently focused on conditions that include cancer-related distress, PTSD and more.

In this episode our hosts explore with Bob how Enveric is working to alleviate the suffering of patients with cancer-related distress, the Company’s recently announced collaboration with the University of Calgary’s Hotchkiss Brain Institute, Enveric’s patent portfolio and the themes and developments within the psychedelic industry that Bob is looking out for through the rest of 2022. 

So sit back and enjoy our conversation with Bob Dagher of Enveric Biosciences. 

Links and mentions in the show

• https://www.enveric.com/ 

Links to the guest’s company and social media accounts

• Enveric’s Twitter: https://twitter.com/Enveric_bio 
• Enveric’s LinkedIn: https://www.linkedin.com/company/EnvericBio/ 
• Bob’s LinkedIn: https://www.linkedin.com/in/bobdaghermd/ 

Show Credits:

This episode was hosted by Anne Donohoe and Nick Opich of KCSA Strategic Communications. 

Special thanks to our Program Director Shea Gunther.

You can learn more about how KCSA Cannabis can help your cannabiz by visiting www.kcsa-cannabis.com or emailing greenrush@kcsa.com. You can also connect with us via our social channels:

Twitter: @The_GreenRush 

Instagram: @thegreenrush_podcast

LinkedIn: https://www.linkedin.com/company/thegreenrushpodcast/ 

Facebook: https://www.facebook.com/TheGreenRushPodcast/ 

YouTube: https://www.youtube.com/channel/UCuEQkvdjpUnPyhF59wxseqw?disable_polymer=true